Table 3. Treatment-emergent adverse events of special interest with both doses of pimasertib (safety population).
| TEAEs, na | Grade 1 | Grade 2 | Totalb |
|---|---|---|---|
| Ocular TEAEs | 7 | ||
| Serous retinal detachment | 6 | 1 | 6 |
| Maculopathy | 1 | 0 | 1 |
| Visual impairment | 1 | 0 | 1 |
| Visual field defect | 1 | 0 | 1 |
| Skin/rash TEAEs | 9 | ||
| Rash | 8 | 1 | 8 |
| Dermatitis | 2 | 1 | 2 |
| Dry skin | 1 | 0 | 1 |
Abbreviation: TEAE=treatment-emergent adverse events.
a
Number of patients with at least one TEAE.
b
Total number of patients: each patient had a grade 1 event, with or without a grade 2 event, n=16. Categories based on a selected list of Medical Dictionary for Regulatory Activities v14 Preferred Terms.